Skip to main content

Table 4 Efficacy outcomes, reported by arm

From: EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Event

Arm A, 100 mg/m2 (n = 79)

Arm B, 125 mg/m2 (n = 79)

Median EFS, mos (90% CI)

8.2 (5.9–8.9)

6.2 (5.8–8.4)#

8.3 (6.2–9.7)

6.4 (5.8–7.7)#

Median EFS pts 75+, mos (90% CI)

8.3 (5.7–8.9)

5.9 (5.1–8.3)#

8.2 (3.5–10.9)

6.9 (5.5–8.3)#

Median PFS, mos (95% CI)

8.3 (5.9–10.5)

8.8 (7.4–10.3)

Median OS, mos (95% CI)

22.4 (17.0–35.6)

20.7 (16.8–28.6)

Best overall response*, n (%)

n = 60

n = 65

CR

4 (7)

1 (2)

PR

20 (33)

26 (40)

SD

24 (40)

18 (28)

PD

9 (15)

14 (21)

NE

3 (5)

6 (9)

  1. CI confidence interval, CR complete response, EFS event-free survival, mos months, NE not evaluable, OS overall survival, PFS progression-free survival, PD progressive disease, PR partial response, SD stable disease
  2. #Based on central review
  3. *Patients with measurable disease